PDF(Pubmed)
Abstract：
Deoxyribonucleic acid (DNA) methylation is one of the epigenetic modifications that has gained a lot of interest as a factor influencing fetal programming and as a biomarker for adverse pregnancy and birth outcomes (APBOs). Epidemiological studies have demonstrated that DNA methylation can result in adverse pregnancy and birth outcomes (APBOs) including miscarriage, intrauterine growth restriction (IUGR), low birth weight (LBW), sepsis, and preterm birth (PTB), which may later result in diseases in adulthood. However, the mechanism by which DNA methylation influences these APBOs remains unclear. The systematic review will assess the association between global and gene-specific DNA methylation with adverse pregnancy outcomes.
The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 checklist will be followed when conducting this systematic review. To develop the search strategy the PI(E)COS (population, intervention/exposure, comparator/control, outcome, and study designs) framework will be followed. Thus far, the research team has retrieved 4721 from Cochrane Library, PubMed, Web of Sciences, and MEDLINE. Out of these, 584 studies have been screened for eligibility, and approximately 124 studies meet the inclusion criteria. Pending the search results identified from the grey literature. For identification of unpublished studies in journals indexed in electronic databases, Google Scholar will be used. I.M and A.S will separately extract data from the articles and screen them, if there are any disagreements between I.M and A.S, then the L.M will resolve them. The methodological quality and bias risk of the included studies will be evaluated using the Critical Appraisal Skill Programme CASP) checklist. [Formula: see text] and [Formula: see text] alpha = 0.10 statistic will be used for assessing statistical heterogeneity between studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess and grade the overall quality of extracted data.
Ethical approval is not required. The systematic review will assess available literature on possible associations between DNA methylation with adverse pregnancy and birth outcomes (APBOs) including LBW, IUGR, miscarriage, sepsis, and PTB. The findings could help guide future research assessing DNA methylation and other APBOs.
PROSPERO CRCRD42022370647.
The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 checklist will be followed when conducting this systematic review. To develop the search strategy the PI(E)COS (population, intervention/exposure, comparator/control, outcome, and study designs) framework will be followed. Thus far, the research team has retrieved 4721 from Cochrane Library, PubMed, Web of Sciences, and MEDLINE. Out of these, 584 studies have been screened for eligibility, and approximately 124 studies meet the inclusion criteria. Pending the search results identified from the grey literature. For identification of unpublished studies in journals indexed in electronic databases, Google Scholar will be used. I.M and A.S will separately extract data from the articles and screen them, if there are any disagreements between I.M and A.S, then the L.M will resolve them. The methodological quality and bias risk of the included studies will be evaluated using the Critical Appraisal Skill Programme CASP) checklist. [Formula: see text] and [Formula: see text] alpha = 0.10 statistic will be used for assessing statistical heterogeneity between studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach will be used to assess and grade the overall quality of extracted data.
Ethical approval is not required. The systematic review will assess available literature on possible associations between DNA methylation with adverse pregnancy and birth outcomes (APBOs) including LBW, IUGR, miscarriage, sepsis, and PTB. The findings could help guide future research assessing DNA methylation and other APBOs.
PROSPERO CRCRD42022370647.
摘要：
背景：脱氧核糖核酸（DNA）甲基化是表观遗传修饰之一，作为影响胎儿程序的因素和不良妊娠和分娩结局（APBO）的生物标志物，已引起了极大的兴趣。流行病学研究表明，DNA甲基化可导致不良妊娠和分娩结局（APBO），包括流产。宫内生长受限（IUGR），低出生体重（LBW），脓毒症,和早产（PTB），这可能会在成年后导致疾病。然而,DNA甲基化影响这些APBO的机制尚不清楚.系统评价将评估全球和基因特异性DNA甲基化与不良妊娠结局之间的关联。
方法：在进行本系统评价时，将遵循系统评价和荟萃分析（PRISMA）2020的首选报告项目清单。制定PI(E)COS(人口，干预/暴露，比较器/控制,结果,和研究设计)框架将遵循。到目前为止,研究小组从Cochrane图书馆检索到4721,PubMed,WebofSciences,和MEDLINE。在这些中，已对584项研究进行了资格筛选，约124项研究符合纳入标准.正在等待从灰色文献中确定的搜索结果。为了在电子数据库索引的期刊中识别未发表的研究，将使用GoogleScholar。I.M和A.S将分别从文章中提取数据并进行筛选，如果I.M和A.S之间有任何分歧,那L.M.就会解决他们.纳入研究的方法学质量和偏倚风险将使用关键评估技能计划CASP）清单进行评估。[公式：见正文]和[公式：见正文]alpha=0.10统计量将用于评估研究之间的统计异质性。建议的分级，评估,发展,和评估（GRADE）方法将用于评估和分级提取数据的整体质量。
背景：不需要道德批准。系统评价将评估有关DNA甲基化与不良妊娠和分娩结局（APBOs）之间可能关联的现有文献，包括LBW。IUGR,流产,脓毒症,和PTB。这些发现可能有助于指导未来评估DNA甲基化和其他APBO的研究。
背景：PROSPEROCRCRD42022370647.
方法：在进行本系统评价时，将遵循系统评价和荟萃分析（PRISMA）2020的首选报告项目清单。制定PI(E)COS(人口，干预/暴露，比较器/控制,结果,和研究设计)框架将遵循。到目前为止,研究小组从Cochrane图书馆检索到4721,PubMed,WebofSciences,和MEDLINE。在这些中，已对584项研究进行了资格筛选，约124项研究符合纳入标准.正在等待从灰色文献中确定的搜索结果。为了在电子数据库索引的期刊中识别未发表的研究，将使用GoogleScholar。I.M和A.S将分别从文章中提取数据并进行筛选，如果I.M和A.S之间有任何分歧,那L.M.就会解决他们.纳入研究的方法学质量和偏倚风险将使用关键评估技能计划CASP）清单进行评估。[公式：见正文]和[公式：见正文]alpha=0.10统计量将用于评估研究之间的统计异质性。建议的分级，评估,发展,和评估（GRADE）方法将用于评估和分级提取数据的整体质量。
背景：不需要道德批准。系统评价将评估有关DNA甲基化与不良妊娠和分娩结局（APBOs）之间可能关联的现有文献，包括LBW。IUGR,流产,脓毒症,和PTB。这些发现可能有助于指导未来评估DNA甲基化和其他APBO的研究。
背景：PROSPEROCRCRD42022370647.
